Olivia Pagani was responsible, at the Institute of Oncology of Southern Switzerland (IOSI), for breast cancer medical treatment and clinical research from 2005 to 2019 and of the Clinic for cancer predisposition and high-risk individuals from 2002 to 2019. From 2013 to 2018 she was director of the IOSI Eusoma and Swiss certified Breast Unit and from 2005 to 2008 co-president of the SAKK (Swiss Group for Cancer Research) breast cancer project group.
She is the current coordinator of the breast cancer programme of the European School of Oncology and breast cancer consultant at Hopital Riviera-Chablais, Rennaz, Vaud.
In April 2017 she was nominated Full Professor at the Medical School University of Geneva and in 2019 Full Professor at the Medical School University of Lugano.
Her main research interests in the last years have been breast cancer in young women and advanced breast cancer.
She is panel member of the ESO-ESMO Advanced Breast Cancer (ABC) and chair of the ESO-ESMO Breast Cancer in Young Women Consensus Conferences (BCY). She has been panel member of the San Gallen International Consensus Conference for Early Breast cancer in 2017 and 2019.
Prof. Pagani was chair of the TEXT trial conducted worldwide by IBCSG, whose results have changed the recommendations for adjuvant endocrine therapy in premenopausal women. She is chair of the POSITIVE study, a global trial evaluating pregnancy in young women with endocrine responsive breast cancer. She was also principal investigator of several SAKK and IBCSG trials.
She is a member of the European Society for Medical Oncology (ESMO).
Updated: October 2021